PAVmed Inc. (PAVM): Nasdaq/NYSE listing notice — PAVmed receives Nasdaq deficiency notice for bid price below $1 per share

PAVmed Inc.

On Dec 29, 2022, Nasdaq notified PAVmed that its common stock bid price closed below $1 for 30 consecutive business days.
Company has 180 calendar days, until June 27, 2023, to regain compliance by having stock close at $1 for 10 consecutive days.
If not compliant by June 27, 2023, PAVmed may be eligible for an additional 180-day period to cure the deficiency.
Nasdaq notice does not currently affect listing of PAVM common stock or PAVMZ warrants; they continue trading.
Company intends to consider all available options to regain compliance with Nasdaq listing standards.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 29, 2022, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain compliance. In order to regain compliance, the clos

View on SEC.gov

Browse all listing & compliance notices →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-037147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.